Advertisement

Familial Hypercholesterolemia Among Young Adults With Acute Coronary Syndrome

Published:October 19, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.09.026
      There are limited data on the prevalence and treatment of familial hypercholesterolemia (FH) among Israeli adults who experience premature acute coronary syndrome (ACS). This study aimed to assess the prevalence of FH among young Israeli adults with ACS, examine the rates of lipid-lowering therapy administration, and determine low-density lipoprotein-cholesterol (LDL-C) levels 1 year after ACS. Patients aged ≤55 years hospitalized for ACS at Meir Medical Center between 2018 and 2019 were included. Probable/definite FH was defined using the Dutch Lipid Clinic criteria. Outcomes included the proportion of patients with probable or definite FH, rate of use of lipid-lowering medications, LDL-C levels 1 year postadmission, and major adverse cardiovascular and cerebrovascular events during 30 months of follow-up. The study population comprised 687 young adults with a median age of 48.5 years. Definite/probable FH was present in 61 patients (8.9%). At 1 year of follow-up, the proportions of patients without FH who had LDL-C levels <70 and <55 mg/100 ml were higher than those of patients with FH (55.9% vs 18%, p <0.001 and 35.8% vs 11.5%, p <0.001, respectively). At 1 year of follow-up, only 47.5% and 22% of patients with FH were treated with ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibitor than were those without FH. The incidence of major adverse cardiovascular and cerebrovascular events was significantly higher among patients with FH. In conclusion, clinically defined FH was present in nearly 1 of 11 patients with premature ACS. There is a necessity for more aggressive lipid-lowering therapies in patients with FH after experiencing ACS.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zimmerman J
        • Duprez D
        • Veach PM
        • Zierhut HA.
        Barriers to the identification of familial hypercholesterolemia among primary care providers.
        J Community Genet. 2019; 10: 229-236
        • Sjouke B
        • Kusters DM
        • Kindt I
        • Besseling J
        • Defesche JC
        • Sijbrands EJ
        • Roeters van Lennep JE
        • Stalenhoef AF
        • Wiegman A
        • de Graaf J
        • Fouchier SW
        • Kastelein JJ
        • Hovingh GK
        Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.
        Eur Heart J. 2015; 36: 560-565
        • Elis A
        • Leventer-Roberts M
        • Bachrach A
        • Lieberman N
        • Durst R
        • Knobler H
        • Balicer R.
        The characteristics of patients with possible familial hypercholesterolemia-screening a large payer/provider healthcare delivery system.
        QJM. 2020; 113: 411-417
        • Bouhairie VE
        • Goldberg AC.
        Familial hypercholesterolemia.
        Cardiol Clin. 2015; 33: 169-179
        • Ito MK
        • Watts GF.
        Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia.
        Drugs. 2015; 75: 1715-1724
        • Grundy SM
        • Stone NJ.
        2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the management of blood cholesterol-secondary prevention.
        JAMA Cardiol. 2019; 4: 589-591
        • Mach F
        • Baigent C
        • Catapano AL
        • Koskinas KC
        • Casula M
        • Badimon L
        • Chapman MJ
        • De Backer GG
        • Delgado V
        • Ference BA
        • Graham IM
        • Halliday A
        • Landmesser U
        • Mihaylova B
        • Pedersen TR
        • Riccardi G
        • Richter DJ
        • Sabatine MS
        • Taskinen MR
        • Tokgozoglu L
        • Wiklund O
        ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J 2020;41:4255].
        Eur Heart J. 2020; 41: 111-188
        • Bucholz EM
        • Rodday AM
        • Kolor K
        • Khoury MJ
        • de Ferranti SD.
        Prevalence and predictors of cholesterol screening, awareness, and statin treatment among US adults with familial hypercholesterolemia or other forms of severe dyslipidemia (1999-2014).
        Circulation. 2018; 137: 2218-2230
        • Singh A
        • Gupta A
        • Collins BL
        • Qamar A
        • Monda KL
        • Biery D
        • Lopez JA
        • de Ferranti SD
        • Plutzky J
        • Cannon CP
        • Januzzi Jr, JL
        • Di Carli MF
        • Nasir K
        • Bhatt DL
        • Blankstein R.
        Familial hypercholesterolemia among young adults with myocardial infarction.
        J Am Coll Cardiol. 2019; 73: 2439-2450
        • Nanchen D
        • Gencer B
        • Muller O
        • Auer R
        • Aghlmandi S
        • Heg D
        • Klingenberg R
        • Räber L
        • Carballo D
        • Carballo S
        • Matter CM
        • Lüscher TF
        • Windecker S
        • Mach F
        • Rodondi N.
        Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes.
        Circulation. 2016; 134: 698-709
        • Versmissen J
        • Oosterveer DM
        • Yazdanpanah M
        • Defesche JC
        • Basart DC
        • Liem AH
        • Heeringa J
        • Witteman JC
        • Lansberg PJ
        • Kastelein JJ
        • Sijbrands EJ.
        Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
        BMJ. 2008; 337: a2423
        • Perez de Isla L
        • Alonso R
        • Watts GF
        • Mata N
        • Saltijeral Cerezo A
        • Muñiz O
        • Fuentes F
        • Diaz-Diaz JL
        • de Andrés R
        • Zambón D
        • Rubio-Marin P
        • Barba-Romero MA
        • Saenz P
        • Sanchez Muñoz-Torrero JF
        • Martinez-Faedo C
        • Miramontes-Gonzalez JP
        • Badimón L
        • Mata P
        SAFEHEART Investigators. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up.
        J Am Coll Cardiol. 2016; 67: 1278-1285
        • Taylor J.
        2012 ESC Guidelines on acute myocardial infarction (STEMI).
        Eur Heart J. 2012; 33: 2501-2502
        • Roffi M
        • Patrono C
        • Collet JP
        • Mueller C
        • Valgimigli M
        • Andreotti F
        • Bax JJ
        • Borger MA
        • Brotons C
        • Chew DP
        • Gencer B
        • Hasenfuss G
        • Kjeldsen K
        • Lancellotti P
        • Landmesser U
        • Mehilli J
        • Mukherjee D
        • Storey RF
        • Windecker S
        ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).
        Eur Heart J. 2016; 37: 267-315
        • Nanchen D
        • Gencer B
        • Auer R
        • Räber L
        • Stefanini GG
        • Klingenberg R
        • Schmied CM
        • Cornuz J
        • Muller O
        • Vogt P
        • Jüni P
        • Matter CM
        • Windecker S
        • Lüscher TF
        • Mach F
        • Rodondi N.
        Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.
        Eur Heart J. 2015; 36: 2438-2445
        • Kramer AI
        • Trinder M
        • Brunham LR.
        Estimating the prevalence of familial hypercholesterolemia in acute coronary syndrome: a systematic review and meta-analysis.
        Can J Cardiol. 2019; 35: 1322-1331
        • Nordestgaard BG
        • Chapman MJ
        • Humphries SE
        • Ginsberg HN
        • Masana L
        • Descamps OS
        • Wiklund O
        • Hegele RA
        • Raal FJ
        • Defesche JC
        • Wiegman A
        • Santos RD
        • Watts GF
        • Parhofer KG
        • Hovingh GK
        • Kovanen PT
        • Boileau C
        • Averna M
        • Borén J
        • Bruckert E
        • Catapano AL
        • Kuivenhoven JA
        • Pajukanta P
        • Ray K
        • Stalenhoef AF
        • Stroes E
        • Taskinen MR
        Tybjærg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. [published correction appears in Eur Heart J 2020;41:4517].
        Eur Heart J. 2013; 34: 3478-3490a
        • Benn M
        • Watts GF
        • Tybjaerg-Hansen A
        • Nordestgaard BG.
        Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication [published correction appears in J Clin Endocrinol Metab 2014;99:4758–4759].
        J Clin Endocrinol Metab. 2012; 97: 3956-3964
        • de Ferranti SD
        • Rodday AM
        • Mendelson MM
        • Wong JB
        • Leslie LK
        • Sheldrick RC.
        Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES).
        Circulation. 2016; 133: 1067-1072
        • Faggiano P
        • Pirillo A
        • Griffo R
        • Ambrosetti M
        • Pedretti R
        • Scorcu G
        • Werren M
        • Febo O
        • Malfatto G
        • Favretto G
        • Sarullo F
        • Antonini-Canterin F
        • Zobbi G
        • Temporelli P
        • Catapano AL
        Centro Studi e Formazione - Italian Association for Cardiovascular Prevention and Rehabilitation. Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: the heredity survey.
        Int J Cardiol. 2018; 252: 193-198
        • Kotseva K
        • Wood D
        • De Bacquer D
        • De Backer G
        • Rydén L
        • Jennings C
        • Gyberg V
        • Amouyel P
        • Bruthans J
        • Castro Conde A
        • Cífková R
        • Deckers JW
        • De Sutter J
        • Dilic M
        • Dolzhenko M
        • Erglis A
        • Fras Z
        • Gaita D
        • Gotcheva N
        • Goudevenos J
        • Heuschmann P
        • Laucevicius A
        • Lehto S
        • Lovic D
        • Miličić D
        • Moore D
        • Nicolaides E
        • Oganov R
        • Pajak A
        • Pogosova N
        • Reiner Z
        • Stagmo M
        • Störk S
        • Tokgözoğlu L
        Vulic D; EUROASPIRE Investigators. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.
        Eur J Prev Cardiol. 2016; 23: 636-648
        • Harada-Shiba M
        • Ako J
        • Arai H
        • Hirayama A
        • Murakami Y
        • Nohara A
        • Ozaki A
        • Uno K
        • Nakamura M.
        Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: results of the EXPLORE-J study.
        Atherosclerosis. 2018; 277: 362-368
        • Barkas F
        • Liberopoulos E
        • Liamis G
        • Elisaf M.
        Familial hypercholesterolemia is undertreated in clinical practice.
        Hellenic J Atheroscler. 2016; 7: 120-130
        • Cannon CP
        • Blazing MA
        • Giugliano RP
        • McCagg A
        • White JA
        • Theroux P
        • Darius H
        • Lewis BS
        • Ophuis TO
        • Jukema JW
        • De Ferrari GM
        • Ruzyllo W
        • De Lucca P
        • Im K
        • Bohula EA
        • Reist C
        • Wiviott SD
        • Tershakovec AM
        • Musliner TA
        • Braunwald E
        Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes.
        N Engl J Med. 2015; 372: 2387-2397
        • Bittner VA
        • Szarek M
        • Aylward PE
        • Bhatt DL
        • Diaz R
        • Edelberg JM
        • Fras Z
        • Goodman SG
        • Halvorsen S
        • Hanotin C
        • Harrington RA
        • Jukema JW
        • Loizeau V
        • Moriarty PM
        • Moryusef A
        • Pordy R
        • Roe MT
        • Sinnaeve P
        • Tsimikas S
        • Vogel R
        • White HD
        • Zahger D
        • Zeiher AM
        • Steg PG
        • Schwartz GG
        ODYSSEY OUTCOMES Committees and Investigators. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome.
        J Am Coll Cardiol. 2020; 75: 133-144
        • Thompson GR
        HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis.
        Atherosclerosis. 2008; 198: 247-255
        • Winters JL.
        Lipid apheresis, indications, and principles.
        J Clin Apher. 2011; 26: 269-275
        • Cohen H
        • Durst R
        • Avizohar O
        • Elis A
        • Arbel Y
        • Bornstein N
        • Bachrach R
        • Bareket R
        • Gavish D
        • Tanne D
        • Lavon E
        • Zafrir B
        • Kamari Y
        • Shechter M
        • Henkin Y
        Updated Israeli guidelines for the treatment of dyslipidemia 2020.
        Harefuah. 2021; 160: 38-44
        • Fitzgerald K
        • White S
        • Borodovsky A
        • Bettencourt BR
        • Strahs A
        • Clausen V
        • Wijngaard P
        • Horton JD
        • Taubel J
        • Brooks A
        • Fernando C
        • Kauffman RS
        • Kallend D
        • Vaishnaw A
        • Simon A.
        A highly durable RNAi therapeutic inhibitor of PCSK9.
        N Engl J Med. 2017; 376: 41-51
        • Raal FJ
        • Kallend D
        • Ray KK
        • Turner T
        • Koenig W
        • Wright RS
        • Wijngaard PLJ
        • Curcio D
        • Jaros MJ
        • Leiter LA
        • Kastelein JJP
        ORION-9 Investigators. Inclisiran for the treatment of heterozygous familial hypercholesterolemia.
        N Engl J Med. 2020; 382: 1520-1530
        • De Backer G
        • Jankowski P
        • Kotseva K
        • Mirrakhimov E
        • Ž Reiner
        • Rydén L
        • Tokgözoğlu L
        • Wood D
        • De Bacquer D
        EUROASPIRE V collaborators; Writing Committee; Scientific Steering/Executive Committee; Coordinating centre; Diabetes centre; Data management centre; Statistical analysis centre; Central laboratory; Study centres, organisations, investigators and other research personnel (National Co-ordinators in each country are indicated by asterisk). Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries.
        Atherosclerosis. 2019; 285: 135-146
        • Ray KK
        • Molemans B
        • Schoonen WM
        • Giovas P
        • Bray S
        • Kiru G
        • Murphy J
        • Banach M
        • De Servi S
        • Gaita D
        • Gouni-Berthold I
        • Hovingh GK
        • Jozwiak JJ
        • Jukema JW
        • Kiss RG
        • Kownator S
        • Iversen HK
        • Maher V
        • Masana L
        • Parkhomenko A
        • Peeters A
        • Clifford P
        • Raslova K
        • Siostrzonek P
        • Romeo S
        • Tousoulis D
        • Vlachopoulos C
        • Vrablik M
        • Catapano AL
        • Poulter NR
        DA VINCI study. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study.
        Eur J Prev Cardiol. 2021; 28: 1279-1289
        • Committee Writing
        • Lloyd-Jones DM
        • Morris PB
        • Ballantyne CM
        • Birtcher KK
        • Daly Jr, DD
        • DePalma SM
        • Minissian MB
        • Orringer CE
        • Smith Jr., SC
        2016 ACC Expert Consensus Decision Pathway on the role of non-Statin therapies for LDL-Cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
        J Am Coll Cardiol. 2016; 68: 92-125
        • Shen X
        • DiMario S
        • Philip K.
        Gender disparities in health resource utilization in patients with atherosclerotic cardiovascular disease: a retrospective cross-sectional study.
        Adv Ther. 2019; 36: 3424-3434
        • Sharifi M
        • Rakhit RD
        • Humphries SE
        • Nair D.
        Cardiovascular risk stratification in familial hypercholesterolaemia.
        Heart. 2016; 102: 1003-1008
        • Béliard S
        • Boccara F
        • Cariou B
        • Carrié A
        • Collet X
        • Farnier M
        • Ferrières J
        • Krempf M
        • Peretti N
        • Rabès JP
        • Varret M
        • Vimont A
        • Charrière S
        • Bruckert E
        • group French FH Registry
        High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: the French familial hypercholesterolemia registry.
        Atherosclerosis. 2018; 277: 334-340
        • Kurihara O
        • Kim HO
        • Russo M
        • Araki M
        • Nakajima A
        • Lee H
        • Takano M
        • Mizuno K
        • Jang IK.
        Relation of low-density lipoprotein cholesterol level to plaque rupture.
        Am J Cardiol. 2020; 134: 48-54
        • Khera AV
        • Won HH
        • Peloso GM
        • Lawson KS
        • Bartz TM
        • Deng X
        • van Leeuwen EM
        • Natarajan P
        • Emdin CA
        • Bick AG
        • Morrison AC
        • Brody JA
        • Gupta N
        • Nomura A
        • Kessler T
        • Duga S
        • Bis JC
        • van Duijn CM
        • Cupples LA
        • Psaty B
        • Rader DJ
        • Danesh J
        • Schunkert H
        • McPherson R
        • Farrall M
        • Watkins H
        • Lander E
        • Wilson JG
        • Correa A
        • Boerwinkle E
        • Merlini PA
        • Ardissino D
        • Saleheen D
        • Gabriel S
        • Kathiresan S.
        Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia.
        J Am Coll Cardiol. 2016; 67: 2578-2589